Antimalarial Drugs Market Research Report Information By Drug Class (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, and Others), By Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malariae, and Plasmodium Ovale), By Mechanism of Action (Treatment for Malaria and Prevention from Malaria) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Antimalarial Drugs Market Overview

Antimalarial Drugs Market Size was valued at USD 0.8 Billion in 2023. The antimalarial drugs market industry is projected to grow from USD 0.9 Billion in 2024 to USD 1.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.00% during the forecast period (2024 - 2032). The high frequency of malaria in developing and poor nations, increased government awareness campaigns, and increased research into novel medications and combination therapies are some of the major market drivers propelling the expansion of antimalarial drugs.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Antimalarial Drugs Market Trends

• Rising prevalence of malaria is driving the market growth

Rising malaria incidence is not only among but also an important factor in the discovery of antimalarial drugs. The acuteness of malaria has bred a need for quick tests, which give prompt outcomes and help in diagnosis. The Malaria epidemic in Africa and Southeast Asia is being fuelled by poor health services and information regarding infectious diseases since these countries continue to suffer from endemic malaria in that year, according to the CDC. The World Health Organization, however, estimates that the number of the world’s population suffering from malaria in 2019 was about 229 million cases. In the light of OECD data, the population of the working age of every second person. It is estimated that close to 3 million people from the global population are susceptible to contracting malaria. However, it should be noted that malaria affects about 1 billion people in Asia-Pacific, which includes Papua New Guinea, India, Nepal, Philippines, the Solomon Islands, Pakistan, Indonesia, Myanmar, Thailand, China, Vietnam, Lao PDR, Cambodia, Bangladesh and of the Republic of Korea. In addition to this, it affects Malaysia too. The CDC's (Centers for Disease Control and Prevention) 2019 report says that the number of malaria cases reported globally is more than 219 million. Moreover, there has been a reported incidence of 1700 cases every year in the United States. It assists in and facilitates early diagnosis as well as treatment through the use of malaria information on the CDC Division of Parasitic Diseases Malaria Diagnostic Website, which is available round the clock.

This market is growing as a result of increased government awareness efforts and research into new antimalarial drugs and therapies. Unlike wise, MMV253 (ZY19489) malaria therapeutics made by medicines for malaria VENTURES were declared as orphan drugs by the Food and Drug Administration in the United States in December 2021. Also, the medications created by Francis Crick Institute and Latvian Institute of Organic Synthesis by the researchers from these institutes in March 2021 are another show of how the scientists have discovered that the drug-like chemical has entirely shut down the crucial steps in the life of malaria parasite. The appearance of new drug candidates to combat malaria will be due to increased drug research and development, and novel antimalarial drugs are expected to grow the market considerably. Another government policy was the launching in June 2021 of the Zero Malaria Starts with Me Campaign, which aimed to put the malaria control program by 2030, one of the targets as revealed in the research. The chart proved that 15% of patients who were admitted to the hospital in Malawi caused unintentional death to those who were infected by the malaria disease. As a result of the preceding intentions then, which will happen on a global level, it is likely that a comparable rise in the global market for anti-malarial drugs will be the result. Thus, driving the antimalarial drugs market revenue.

Antimalarial Drugs Market Segment Insights

Antimalarial Drugs Drug Class Insights

The Antimalarial Drugs Market segmentation, based on drug class, includes Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, and Others. In 2023, the antifolate compounds segment dominated the market because of its potency against the malaria parasite. Antifolate medicines, such as sulfadoxine-pyrimethamine, act by inhibiting folate synthesis, which is necessary for the malaria parasite's growth and reproduction. This focused strategy affects the parasite's life cycle, making it a valuable and frequently used class of medications for malaria therapy and prevention.

Antimalarial Drugs Malaria Type Insights

The Antimalarial Drugs Market segmentation, based on malaria type, includes Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malariae, and Plasmodium Ovale. In 2023, the Plasmodium Falciparum segment dominated the market. Malaria has severe and frequently fatal consequences, particularly in areas with high malaria transmission, such as Sub-Saharan Africa. Because of the clinical importance of Plasmodium falciparum and its involvement in a high percentage of malaria-related deaths, there is an emphasis on creating effective treatments to lower the overall burden of this parasite.

Antimalarial Drugs Mechanism of Action Insights

The Antimalarial Drugs Market segmentation, based on the mechanism of action, includes Treatment for Malaria and Prevention of Malaria. The treatment for malaria category generated the most income in 2023, driven by the sudden need for improved malaria therapies. This phase is critical in treating both simple and severe cases, with the goal of relieving symptoms, eliminating parasites, and preventing relapses. Given malaria's global prevalence and impact on public health, there is an ongoing demand for antimalarial drugs that provide rapid and effective treatment, thereby contributing to the decrease of malaria-related morbidity and mortality.

Figure 1: Antimalarial Drugs Market, by Mechanism of Action, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Antimalarial Drugs Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American antimalarial drugs market area will dominate this market. The existence of large pharmaceutical companies and substantial healthcare spending make the North American region a prominent market for antimalarial drugs. Exports primarily drive the market to countries where malaria is endemic, notwithstanding the low prevalence of malaria in this region.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.

Figure 2: Antimalarial Drugs Market Share By Region 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's antimalarial drugs market accounts for the second-largest market share because of the high volume of visitors from Europe to areas where malaria is endemic. The existence of significant pharmaceutical businesses in the area is another factor driving the market. Further, the German antimalarial drugs market held the largest market share, and the UK antimalarial drugs market was the fastest growing market in the European region.

The Asia-Pacific Antimalarial Drugs Market is expected to grow at the fastest CAGR from 2024 to 2032 because malaria is a highly prevalent disease in the area. Due to the huge population risk of malaria in nations like China and India, there is a significant market need for antimalarial drugs. Moreover, China’s antimalarial drugs market held the largest market share, and the Indian antimalarial drugs market was the fastest growing market in the Asia-Pacific region.

Antimalarial Drugs Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the antimalarial drugs market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the antimalarial drugs industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global antimalarial drugs industry to benefit clients and increase the market sector. In recent years, the antimalarial drugs industry has offered some of the most significant advantages to medicine. Major players in the antimalarial drugs market are attempting to increase market demand by investing in research and development operations, including Novartis AG, Mylan N.V., Pfizer Inc., Sanofi, GlaxoSmithKline plc, Cipla Inc., Ipca Laboratories Ltd, Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd., and Others.

Located in Mumbai, India, Ipca Laboratories Limited is a worldwide pharmaceutical firm. Throughout more than 120 nations on six continents, the firm has been an essential healthcare partner. This pharmaceutical company is completely integrated, producing more than 80 APIs and 350 formulations for different therapeutic areas. Additionally, the company is among the biggest producers and providers of more than a dozen APIs worldwide. The most exacting drug regulatory bodies in the world, including the UK-MHRA, EDQM-Europe, and WHO-Geneva, have approved these completely automated production facilities where these are made from scratch.

The healthcare business Novartis AG (Novartis) is dedicated to the research, development, production, and distribution of pharmaceutical products, both brand-name and generic, as well as eye care items. It offers medications to treat a variety of illnesses, including solid tumors, immunological disorders, infections, neurological disorders, ophthalmology and respiratory diseases, cardiovascular diseases, dermatological issues, and hematologic diseases. Targeting both adults and children suffering from malaria, Novartis and Medicines for Malaria Venture made the decision in November 2022 to move on with a Phase 3 clinical trial for the novel lumefantrine/ganaplacide-SDF combo.

Key Companies in the antimalarial drugs market include

• Novartis AG


• Mylan N.V.


• Pfizer Inc.


• Sanofi


• GlaxoSmithKline plc


• Cipla Inc.


• Ipca Laboratories Ltd


• Hoffmann-La Roche Ltd


• Sun Pharmaceutical Industries Ltd.

Antimalarial Drugs Industry Developments

August 2022: The University of Surrey will get funding from the British Heart Foundation to investigate how anti-malaria medications affect heart rhythm. It is to comprehend the effects of malaria medications on the human heart.

March 2022: Australia has approved tafenoquine, a novel medication that treats a specific kind of malaria. Medicines for Malaria Venture (MMV) collaborated with GlaxoSmithKline (GSK) to develop the medication for use in children and adolescents. The medication is used in conjunction with chloroquine, a conventional malaria treatment.

Antimalarial Drugs Market Segmentation

Antimalarial Drugs Drug Class Outlook

• Aryl Aminoalcohol Compounds


• Antifolate Compounds


• Artemisinin Compounds


• Others

Antimalarial Drugs Malaria Type Outlook

• Plasmodium Falciparum


• Plasmodium Vivax


• Plasmodium Malariae


• Plasmodium Ovale

Antimalarial Drugs Mechanism of Action Outlook

• Treatment for Malaria


• Prevention from Malaria

Antimalarial Drugs Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America